BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.

South San Francisco-based Allogene Therapeutics released some early data from the company’s UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.

Shares of Bellicum Pharmaceuticals plunged following an announcement that the company will slash 79% of employees as part of a restructuring following the developmental pause for one CAR-T program.

A new form of treatment known as CAR-T cell therapy has been making waves in the field of oncology, and clinical trials have begun for patients with Malignant Pleural Mesothelioma (MPM).

Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review for idecabtagene vicleucel.

Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.

The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies. 

T-knife GmbH, based in Berlin, Germany, closed a €66 million ($78.4 million) Series A round led by Versant Ventures and RA Capital Management.

Novartis CAR-T cell therapy Kymriah met the primary endpoint at an interim analysis of a phase II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said.

Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.